Skip to main content

Table 1 All of the factors involved in blood malignancies among Iranian population

From: Genetics of blood malignancies among Iranian population: an overview

STUDY (ET AL)

Year

Type

Gene

population

Results

Prediction

izadifar [27]

2018

AML

PVT1

134 patients

40 controls

Over expression in AML-M3

Diagnosis

pashaiefar [28]

2018

AML

IRAIN

64 patients

51 controls

Under expression.

Poor prognosis

ahmadi [29]

2018

CLL

MALAT1

30 patients

30 controls

Over expression.

Diagnosis

bahari [30]

2018

ALL

PAX8-AS1

110 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

hashemi [31]

2016

ALL

Lnc-LAMC2

110 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

koolivand [32]

2018

AML

miR-155

25 patients

25 controls

Over expression.

Poor prognosis

fathullahzadeh [33]

2016

CLL

miR-192

20 patients

20 controls

Under expression.

Diagnosis

hashemi [34]

2016

ALL

miR-34b/c

110 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

fallah [35]

2015

CML

miR-155, miR-106, miR-16-1, miR-15a, miR-101, and miR-568

50 patients

MiR-155 and miR-106 under expressions. MiR-16-1, miR-15a, miR-101, and miR-568 over expressions.

Diagnosis and prognosis

seyyedi [36]

2016

AML

miR-1, miR-486, and let-7a

45 patients

Over expressions.

Diagnosis

hasani [37]

2014

ALL

miR-146a

75 patients

115 controls

Polymorphism was correlated with tumor progression.

Diagnosis

hashemi [38]

2017

ALL

DROSHA

75 patients

115 controls

Polymorphism was correlated with tumor progression.

Diagnosis

farzaneh [39]

2016

CLL and ALL

DICER

51 patients

29 controls

Under expression.

Diagnosis

rahmani [40]

2017

ALL

DNMT1

45 patients

Methylation.

Poor prognosis

allahbakhshian [41]

2018

ALL

IL-6 and IFN-γ

52 patients

13 controls

IFN-γ under expression in ALL. IL-6 under expression in T-ALL.

Diagnosis

ghavami [42]

2018

ALL

IL-27

200 patients

210 controls

Polymorphism was correlated with tumor progression.

Poor prognosis

kouzegaran [43]

2018

CLL

IL-17A and IL-22

78 patients

28 controls

Over expressions.

Diagnosis

sepehrizadeh [44]

2014

AML

IL-1β, IL-8, IL-10, and IFN-γ

46 patients

IL-1β, IL-8, and IL-10 under expressions after chemotherapy. IFN-γ over expression after chemotherapy.

Diagnosis

amirzargar [45]

2005

CML

TGF-β, IL-4, and IL-10

30 patients

40 controls

TGF-β over expression. IL-4 and IL-10 under expressions.

Diagnosis

abdolmaleki [46]

2018

AML

PD-1 and CD244

30 patients

15 controls

Over expressions.

Diagnosis

taghiloo [47]

2017

CLL

GAL-9 and PD-L1

25 patients

15 controls

Over expressions.

Poor prognosis

amirghofran [48]

2001

AML

CD11b

70 patients

Correlation with survival.

Diagnosis

ramzi [49]

2018

AML, ALL, CML

CTLA-4, CD28, and PD-1

59 patients

46 controls

Polymorphisms were correlated with tumor progression.

Diagnosis

nasiri [50]

2013

ALL, NHL

TNF-α and LT-α

138 patients

130 controls

Polymorphisms were correlated with tumor progression.

Diagnosis

orouji [51]

2012

ALL

HLA-D

135 patients

150 controls

Allele frequencies were correlated with tumor progression.

Diagnosis

rezvany [52]

2007

CLL

HLA-G

74 patients

12 controls

Over expression.

Diagnosis

amirzargar [53]

2007

CML

HLA-D

50 patients

80 controls

Allele frequencies were correlated with tumor progression.

Diagnosis

khosravi [54]

2007

CML

HLA-D

50 patients

180 controls

Allele frequencies were correlated with tumor progression.

Diagnosis

sarafnejad [55]

2006

AML

HLA-D

60 patients

180 controls

Allele frequencies were correlated with tumor progression.

Diagnosis

moazzeni [56]

1999

CLL

HLA-B and HLA-D

32 patients

Allele frequencies were correlated with tumor progression.

Diagnosis

shahsavar [57]

2010

AML and ALL

KIR2DS3

78 patients

200 controls

Genotype frequencies were correlated with tumor progression.

Diagnosis

noori-daloii [58]

2013

GVHD

IL-1α, IL-4Rα, and IL-12

91 patients

Polymorphisms were correlated with tumor progression.

Good prognosis

kazemi [59]

2009

ALL

FCRL1–5

73 patients

35 controls

Under expressions.

Diagnosis

pouyanrad [60]

2019

ALL

miR-335-5p

64 patients

30 controls

Under expression.

Poor prognosis

rahgozar [61]

2014

ALL

ABCA3, ABCA2, MRD1, and MRP1

27 patients

15 controls

Were correlated with drug resistance.

Poor prognosis

mahjoubi [62]

2008

AML and ALL

MRP1

52 patients

10 controls

Correlation with poor clinical outcomes.

Poor prognosis

mahjoubi [63]

2012

ALL

MRP1

42 patients

10 controls

Over expression.

Poor prognosis

ghodousi [64]

2018

ALL

miR-326 and miR-200c

46 patients

16 controls

Under expressions.

Poor prognosis

mesrian tanha [65]

2017

ALL

ABCC4

145 patients

Polymorphism was correlated with tumor progression.

Poor prognosis

kazemi [66]

2018

Leukemia

HO-1

63 patients

Genotype frequencies were correlated with tumor progression.

Good prognosis

saadat [67]

2000

ALL

GSTM1

38 patients

75 controls

Allele frequencies were correlated with tumor progression.

Diagnosis

seghatoleslam [68]

2014

ALL

UBE2Q1

20 patients

20 controls

Under expression.

Diagnosis

seghatoleslam [69]

2012

ALL

UBE2Q2

20 patients

20 controls

Over expression.

Diagnosis

zareifar [70]

2018

AML

Livin and BIRC5

43 patients

Correlation with poor prognosis.

Poor prognosis

rostami [71]

2017

AML

APAF1

101 patients

50 controls

Methylation.

Diagnosis

asgarian-omran [72]

2010

CLL

GAL-3

85 patients

Under expression.

Poor prognosis

daneshbod [73]

2005

AML

BCL-2

70 patients

Correlation with survival.

Poor prognosis

zare-abdollahi [74]

2016

AML

BECN1

128 patients

Under expression.

Prognosis

amirghofran [75]

2009

ALL

BCL-2

50 patients

Correlation with poor prognosis.

Poor prognosis

younesian [76]

2017

ALL

RASSF6

45 patients

Methylation.

Poor prognosis

pashaiefar [77]

2018

AML

PARP1

65 patients

54 controls

Over expression.

Poor prognosis

pashaiefar [78]

2018

AML

PARP1

78 patients

19 controls

Over expression.

Poor prognosis

bahari [79]

2016

ALL

MTHFR

100 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

bahari [80]

2016

ALL

SHMT1

120 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

bahari [81]

2017

ALL

FHIT

100 patients

120 controls

Methylation.

Diagnosis

kamali dolatabadi [82]

2017

AML

CDKN2B

59 patients

Methylation.

Diagnosis

memarian [83]

2012

ALL

WNT-7B, WNT-9A, WNT-16B, WNT-2B, WNT-5A, WNT-7A, WNT-10A

71 patients

36 controls

WNT-7B, WNT-9A, and WNT-16B over expressions. WNT-2B, WNT-5A, WNT-7A, and WNT-10A under expressions.

Diagnosis

memarian [84]

2009

CLL

WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, WNT-16B, WNT-7A

62 patients

11 controls

WNT-3, WNT-4, WNT-5B, WNT-7B, WNT-9A, WNT-10A, and WNT-16B over expressions. WNT-7A under expression.

Diagnosis

memarian [85]

2007

AML

WNT-3, WNT-7A, Wnt-10A

16 patients

36 controls

WNT-3 over expression. WNT-7A and Wnt-10A under expressions.

Diagnosis

ghasemi [86]

2015

AML

SFRP1, SFRP2

43 patients

25 controls

Methylation.

Diagnosis

gholami [87]

2014

AML

LATS2

32 patients

10 controls

Over expression.

Poor prognosis

rafiee [88]

2016

AML

RSK4

40 patients

10 controls

Under expression.

Poor prognosis

salarpour [89]

2017

AML

CEBPA, RUNX-1

96 patients

18 controls

CEBPA and RUNX-1 over expressions.

Diagnosis

ayatollahi [90]

2017

AML

WT1

126 patients

Over expression.

Diagnosis

rezai [91]

2015

Leukemia

WT1

12 patients

12 controls

Over expression.

Diagnosis

asgarian omran [92]

2008

ALL

WT1

116 patients

36 controls

Over expression.

Diagnosis

bahari [93]

2016

ALL

IKZF1

110 patients

120 controls

Polymorphism was correlated with tumor progression.

Diagnosis

rezaei [94]

2017

AML

FLT3, NPM1

70 patients

Mutation.

Diagnosis

nasiri [95]

2014

AML

FLT3

27 patients

Mutation.

Diagnosis

pazhakh [96]

2011

AML

NPM1

131 patients

Mutation.

Diagnosis

zaker [97]

2010

AML

FLT3, KIT

212 patients

Mutation.

Diagnosis

jafari ghahfarokhi [98]

2014

CLL

ZAP70

66 patients

Over expression.

Good prognosis

shabani [99]

2008

ALL

ROR1, WT1

51 patients

Over expressions.

Diagnosis

aliparasti [100]

2013

AML

VEGF-C

27 patients

28 controls

Under expression.

Diagnosis

amirpour [101]

2016

AML

BAALC

47 patients

47 controls

Over expression.

Poor prognosis

nadimi [102]

2016

ALL, AML

BAALC

145 patients

Polymorphism was correlated with tumor progression.

Poor prognosis

mobasheri [103]

2006

ALL

TSGA10

52 patients

Expression in ALL cases.

Diagnosis and prognosis

hoseinkhani [104]

2019

AML

TSGA10, HIF-1α

30 patients

10 controls

TSGA10 under expression. HIF-1α over expression.

Diagnosis